# Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma

> **NCT00193193** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 100 (—)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Estramustine
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00193193
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2003-12
- **Final completion:** 2007-02
- **Target enrollment:** 100 (—)
- **Last updated:** 2010-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193193, "Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT00193193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*